HC Wainwright Forecasts FibroBiologics Q3 Earnings

FibroBiologics, Inc. (NASDAQ:FBLG) – Equities research analysts at HC Wainwright issued their Q3 2024 EPS estimates for FibroBiologics in a research report issued on Wednesday, October 30th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for FibroBiologics’ Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at ($0.73) EPS and FY2028 earnings at ($0.70) EPS.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09).

A number of other research analysts have also recently weighed in on the stock. Maxim Group initiated coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a “buy” rating and a $12.00 price objective for the company. EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $3.18 on Friday. The firm has a 50-day moving average price of $2.72 and a two-hundred day moving average price of $5.44. FibroBiologics has a twelve month low of $1.08 and a twelve month high of $55.00.

Hedge Funds Weigh In On FibroBiologics

Institutional investors and hedge funds have recently modified their holdings of the company. Mercer Global Advisors Inc. ADV purchased a new stake in FibroBiologics in the 2nd quarter worth approximately $51,000. Cahaba Wealth Management Inc. acquired a new position in FibroBiologics in the second quarter valued at $73,000. Saxon Interests Inc. purchased a new position in FibroBiologics during the second quarter worth about $106,000. Rhumbline Advisers acquired a new stake in FibroBiologics in the 2nd quarter worth about $115,000. Finally, Symphony Financial Ltd. Co. purchased a new stake in FibroBiologics in the 3rd quarter valued at about $76,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.